Cyclin-dependent kinase 4/6 inhibition in the treatment of hormone receptor-positive breast cancer
Rugo, H.S.
Clinical Advances in Hematology and Oncology H&o 17(10): 555-558
2019
ISSN/ISBN: 1543-0790 PMID: 31730581 Document Number: 699852
Document emailed within 1 workday
Related Documents
Ohta, T.; Okamoto, K.; Isohashi, F.; Shibata, K.; Fukuda, M.; Yamaguchi, S.; Xiong, Y. 1998: T-loop deletion of CDC2 from breast cancer tissues eliminates binding to cyclin B1 and cyclin-dependent kinase inhibitor p21 Cancer Research 58(6): 1095-1098Songia, S.; Mortellaro, A.; Taverna, S.; Fornasiero, C.; Scheiber, E.A.; Erba, E.; Colotta, F.; Mantovani, A.; Isetta, A.M.; Golay, J. 1997: Characterization of the new immunosuppressive drug undecylprodigiosin in human lymphocytes: retinoblastoma protein, cyclin-dependent kinase-2, and cyclin-dependent kinase-4 as molecular targets Journal of Immunology 158(8): 3987-3995
Liang, B.; Wang, S.; Yang, X.; Ye, Y.; Yu, Y.; Cui, Z. 2003: Expressions of cyclin E, cyclin dependent kinase 2 and p57(KIP2) in human gastric cancer Chinese Medical Journal 116(1): 20-23
Gussio, R.; Zaharevitz, D.W.; McGrath, C.F.; Pattabiraman, N.; Kellogg, G.E.; Schultz, C.; Link, A.; Kunick, C.; Leost, M.; Meijer, L.; Sausville, E.A. 2000: Structure-based design modifications of the paullone molecular scaffold for cyclin-dependent kinase inhibition Anti-Cancer Drug Design 15(1): 53-66
Partridge, A.H.; Niman, S.M.; Ruggeri, M.; Peccatori, F.A.; Azim, H.A.; Colleoni, M.; Saura, C.; Shimizu, C.; Sætersdal, A.B.; Kroep, J.R.; Mailliez, A.; Warner, E.; Borges, V.F.; Amant, F.éd.ér.; Gombos, A.; Kataoka, A.; Rousset-Jablonski, C.; Borstnar, S.; Takei, J.; Lee, J.E.; Walshe, J.M.; Borrego, M.R.íz.; Moore, H.C.; Saunders, C.; Cardoso, F.; Susnjar, S.; Bjelic-Radisic, V.; Smith, K.L.; Piccart, M.; Korde, L.A.; Goldhirsch, A.; Gelber, R.D.; Pagani, O. 2021: Who are the women who enrolled in the POSITIVE trial: a global study to support young hormone receptor positive breast cancer survivors desiring pregnancy Breast 59: 327-338
Koyama, H.; Iesato, A.; Fukushima, Y.; Okada, T.; Watanabe, T.; Harada, M.; Ito, T.; Maeno, K.; Mochizuki, Y.; Ito, K.; Amano, J. 2011: A retrospective study of high-dose toremifene treatment for patients with aromatase inhibitor refractory advanced or metastatic hormone receptor-positive breast cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 38(7): 1123-1126
Zhang, K.; Kumar, R. 1994: Interferon-alpha inhibits cyclin E- and cyclin D1-dependent CDK-2 kinase activity associated with RB protein and E2F in Daudi cells Biochemical and Biophysical Research Communications 200(1): 522-528
Salh, B.; Bergman, D.; Marotta, A.; Pelech, S.L. 1999: Differential cyclin-dependent kinase expression and activation in human colon cancer Anticancer Research 19(1b): 741-748
Hajdúch, M.; Havlíèek, L.; Veselý, J.; Novotný, R.; Mihál, V.; Strnad, M. 1999: Synthetic cyclin dependent kinase inhibitors. new generation of potent anti-cancer drugs Advances in Experimental Medicine and Biology 457: 341-353
Sutepvarnon, A.; Warnnissorn, M.; Srimuninnimit, V. 2013: Predictive value of Ki67 for adjuvant chemotherapy in node-negative, hormone receptor-positive breast cancer Journal of the Medical Association of Thailand 96(Suppl 2): S60-S66
Wang, L.Q.; Zhao, W.D.; Jiao, X.J.; Du, D.L.; Liu, Y.S. 2016: Positive expression of insulin-like growth factor-1 receptor is associated with a positive hormone receptor status in ovarian cancer European Journal of Gynaecological Oncology 37(2): 204-210
Tanguay, D.; Pavlovic, S.; Piatelli, M.J.; Bartek, J.; Chiles, T.C. 1999: B cell antigen receptor-mediated activation of cyclin-dependent retinoblastoma protein kinases and inhibition by co-cross-linking with Fc gamma receptors Journal of Immunology 163(6): 3160-3168
Wu, L.; Yee, A.; Liu, L.; Carbonaro-Hall, D.; Venkatesan, N.; Tolo, V.T.; Hall, F.L. 1994: Molecular cloning of the human CAK1 gene encoding a cyclin-dependent kinase-activating kinase Oncogene 9(7): 2089-2096
Akagi, T.; Ono, H.; Shimotohno, K. 1996: Tyrosine kinase inhibitor herbimycin A reduces the stability of cyclin-dependent kinase Cdk6 protein in T-cells Oncogene 13(2): 399-405
Altundag, K. 2018: Concurrent administration of aromatase inhibitors with chemotherapy might show better outcome in high risk hormone-receptor positive early-stage breast cancer patients Journal of Buon: Official Journal of the Balkan Union of Oncology 23(5): 1559-1560
Nikoleishvili, D.; Pertia, A.; Tsintsadze, O.; Gogokhia, N.; Chkhotua, A. 2007: Down-regulation of p27(Kip 1) cyclin-dependent kinase inhibitor in prostate cancer: distinct expression in various prostate cells associating with tumor stage and grades Georgian Medical News 143: 34-38
Joe, A.K.; Memeo, L.; Mckoy, J.; Mansukhani, M.; Liu, H.; Avila-Bront, A.; Romero, J.; Li, H.; Troxel, A.; Hibshoosh, H. 2005: Cyclin D1 overexpression is associated with estrogen receptor expression in Caucasian but not African-American breast cancer Anticancer Research 25(1a): 273-281
Wang, S.-l.; Li, Y.-x.; Song, Y.-w.; Wang, W.-h.; Jin, J.; Liu, Y.-p.; Liu, X.-f.; Yu, Z.-h. 2010: Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy Zhonghua Zhong Liu Za Zhi 32(7): 520-525
Paciotti, G.F.; Tamarkin, L. 1988: Interleukin-2 differentially affects the proliferation of a hormone-dependent and a hormone-independent human breast cancer cell line in vitro and in vivo Anticancer Research 8(6): 1233-1239
Lubec, B.; Arbeiter, K.; Hoeger, H.; Lubec, G. 1996: Increased cyclin dependent kinase in aortic tissue of rats fed homocysteine Thrombosis and Haemostasis 75(4): 542-545